olaparib

Org: KSQ Therapeutics, Cambridge, MA, Roche Pharma Research and Early Development, Roche Innovation Center, Dana-Farber Cancer Institute, Hackensack University Medical Center,

Abstract

Phase II randomized multi-centre study of neoadjuvant olaparib in patients with platinum sensitive relapsed high grade serous ovarian cancer: The NEO trial.

Org: Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, Auckland City Hospital and University of Auckland, Auckland, New Zealand,

Abstract

Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A).

Org: AstraZeneca, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Dana-Farber Cancer Institute,

Abstract

Incidence and time to onset of immunotherapy-related adrenal insufficiency in the I-SPY2 trial.

Org: University of Chicago Medicine, University of Chicago, University of California, San Francisco Department of Medicine, University of California, San Francisco Department of Surgery, University of California, San Francisco,

Abstract

Mind the gap: Estimating the opportunity lost due to the gap between FDA and EMA cancer drug approvals.

Org: Lifespan Cancer Institute, Brown University School of Medicine-Rhode Island Hospital, Rhode Island Hospital, Stanford University School of Medicine, The University of Texas MD Anderson Cancer Center,

Abstract

Efficacy and safety of olaparib in patients with tumors harboring alterations in homologous recombination repair pathway associated genes: Results from the Drug Rediscovery Protocol.

Org: Department of Medical Oncology, Erasmus Medical Cancer Institute, Rotterdam, Netherlands, Radboud University Medical Center, Nijmegen, Netherlands, Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands, Department of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, Netherlands, Department of medical oncology, Leiden University Medical Center, Leiden, Netherlands,

Abstract

BRCA1/2 reversion mutations (BRCArev) in advanced prostate cancer in the absence of prior PARP inhibitor (PARPi) therapy.

Org: Foundation Medicine, Inc., Cambridge, MA, Cedars-Sinai Medical Center, SUNY Upstate Medical University, University of California, San Diego Health,

Abstract

Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer (EC) in DUO-E: Results by BRCA1/BRCA2 mutation (BRCAm) status.

Org: UZ Leuven and BGOG, Cliniques Universitaires Saint-Luc and BGOG, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, FirstHealth Moore Regional Hospital, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, and GOG Foundation (GOG-F),

Abstract

Efficacy of olaparib combined to metronomic cyclophosphamide and metformin in patients with recurrent advanced/metastatic endometrial by molecular subtypes: ENDOLA phase I/II trial.

Org: Gustave-Roussy Cancer Campus, Centre Antoine-Lacassagne, Pole Santé Publique, Pharmacie, URCC,

Abstract

A phase II trial of olaparib and durvalumab in patients with recurrent IDH-mutated gliomas.

Org: London Regional Cancer Program,

Abstract

Rapid label expansion based on public-private collaboration in IMPRESS-Norway.

Org: Oslo University Hospital-Norwegian Radium Hospital, Department of Cancer Immunology, The Arctic University of Norway, Centre for Cancer Biomarkers CCBIO,

Abstract

A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune).

Org: Department of Urology, University of California, San Diego,

Abstract

Safety and tolerability of durvalumab + carboplatin/paclitaxel followed by durvalumab ± olaparib in patients with newly diagnosed advanced or recurrent endometrial cancer (EC) in the DUO-E/GOG-3041/ENGOT-EN10 trial.

Org: Minnesota Oncology, Maplewood, MN, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL, FirstHealth Moore Regional Hospital, Pinehurst, NC, Oklahoma Cancer Specialists and Research Institute, Tulsa, OK, Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea,

Abstract

The efficacy of PARP inhibitors in the treatment of patients with synchronous breast cancer.

Org: Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology, Tashkent, Uzbekistan, Republican Specialized Scientific and Practical Center of Oncology and Radiology, Tashkent, Uzbekistan, Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology, Toshkent, Uzbekistan,

Abstract

Real-world biomarker testing, treatment patterns and outcomes in a US cohort of patients with advanced ovarian cancer.

Org: AstraZeneca Pharmaceuticals LP,

Abstract

A phase IV trial to confirm the efficacy of olaparib in combination with bevacizumab as maintenance frontline treatment of HRD-positive ovarian tumours (IOlanTHe).

Org: Humanitas University + IRCCS Humanitas Research Hospital, Unit of Gynaecological Oncology Research, University of Milan-Bicocca and Gynecologic Oncology Program, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Obstetrics and Gynecology Unit ASO Ordine Mauriziano,

Abstract

Overall survival (OS) in patients with platinum-sensitive relapsed ovarian cancer (PSROC) treated with olaparib maintenance monotherapy: Update from the L-MOCA trial.

Org: Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Department of Gynecologic Oncology, Cancer Hospital of The University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China, Department of Gynecologic Oncology, Anhui Provincial Cancer Hospital, Hefei, China, Department of Gynecologic Oncology, Hubei Cancer Hospital, Wuhan, China, Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China,

Abstract

Role of the receptor for advanced glycation end products (RAGE) in blood as a potential biomarker for progression to olaparib: A post hoc analysis of patients with platinum-resistant ovarian cancer (PROC) treated in the ROLANDO-GEICO 1601 trial.

Org: Department of Medical Oncology, Hospital Clínico Universitario de Valencia, Valencia, Spain, Laboratory of Translational Oncology, Program in Solid Tumors, Cima-Universidad de Navarra, Cancer Center Clínica Universidad de Navarra CCUN, Navarra Institute for Health Research IdISNA, Department of Pathology, Anatomy & Physiology, Navarra University, Pamplona, Spain,

Abstract

A phase II study evaluating the effect of IMNN-001 on second-look laparoscopy (SLL) when administered in combination with bevacizumab (BEV) and neoadjuvant chemotherapy (NACT) in patients newly diagnosed with advanced epithelial ovarian cancer (EOC).

Org: Imunon, Inc.,

Abstract

PROact: A prospective phase II study to evaluate olaparib plus abiraterone and prednisone combination therapy in patients with metastatic hormone sensitive prostate cancer with HRR gene mutation.

Org: Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Institute of Urology, Nanjing University, Nanjing, China,

Abstract

Neoadjuvant combination treatment of olaparib and pembrolizumab for patients with HRD-positive advanced ovarian cancer.

Org: Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan, Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan, Department of Gynecology, NHO Shikoku Cancer Center, Matsuyama, Japan, Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan, Department of Gynecology, National Cancer Center Hospital East, Kashiwa, Japan,

Abstract

Targeting the CD47/TSP-1 axis: A promising strategy for patients with ovarian cancer (OC) that relapses on PARP inhibitors (PARPi).

Org: Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Apmonia Therapeutics, CNRS UMR 7369 MEDyC - Reims University,

Abstract

Olaparib, AZD1390, ceralasertib, saruparib and consolidation durvalumab (CONCORDE) phase Ib platform study of novel DNA damage response inhibitor (DDRi) agents in combination with radiotherapy in non-small cell lung cancer (NSCLC).

Org: University of Newcastle,

Abstract

HOPE: Harnessing olaparib, palbociclib, and endocrine therapy for BRCA1/2-associated HR+, HER2- metastatic breast cancer.

Org: Penn Medicine Abramson Cancer Center, University of Pennsylvania, Abramson Cancer Center, Hospital of the University of Pennsylvania, Memorial Sloan Kettering Cancer Center,

Abstract

Risk assessment of myelosuppression with PARP inhibitors in prostate cancer: Insights from FAERS.

Org: Cincinnati Children s Hospital Medical Center,

Abstract

TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2.

Org: Breast Medicine Service,

Abstract

Overall survival in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer (PSROC) treated with olaparib maintenance: Real-world data of the C-PATROL study.

Org: Med. Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany, Oncologic Medical Center at the Jerusalem Hospital Hamburg, Hamburg, Germany, Hospital Aschaffenburg GmbH, Aschaffenburg, Germany, North-Eastern German Society of Gynaecological Oncology (NOGGO) and Department of Gynecology with Center for Oncological Surgery, Charité-University Medicine of Berlin, Campus Virchow Klinikum, Berlin, Germany, National Center for Tumor Diseases (NCT), Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany,

Abstract

Evaluation of a novel signature for PARP inhibitor sensitivity prediction using real-world data.

Org: Zephyr AI, Mclean, VA,

Abstract

Biomarkers associated with outcomes from KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) versus next-generation hormonal agent (NHA) in previously treated metastatic castration-resistant prostate cancer (mCRPC).

Org: Severance Hospital Yonsei University Health System, University of Auckland, Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, National Yang Ming Chiao Tung University,

Abstract

Analysis of glycemia during olaparib therapy in patients with ovarian cancer.

Org: University of Medical Sciences Poznan,

Abstract

Examination of in vitro and in vivo antitumor activity of PARP1 selective inhibitor D0112-005.

Org: Chengdu Easton Biopharmaceuticals Co., Ltd.,

Abstract

AURKA blockage as a strategy to overcome resistance to olaparib and platinum in high-grade ovarian cancer (HGOC).

Org: Translational Oncology and Pathology Group, La Paz University Hospital-IdiPAZ, Instituto de Investigación Sanitaria (INCLIVA), Hospital La Paz, Center for Biomedical Research in the Cancer Network (Centro de Investigación Biomédica en Red de Cáncer, CIBERONC),

Abstract

Synergistic cytotoxicity of histone deacetylase, poly-ADP ribose polymerase inhibitors and decitabine in breast and ovarian cancer cells: Therapeutic implications.

Org: Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,

Abstract

A systematic literature review and indirect treatment comparison of PARP inhibitors in combination with next-generation hormonal agents in BRCA-mutated metastatic castration‑resistant prostate cancer.

Org: Mtech Access,

Abstract

A phase II, open-label, efficacy and safety of olaparib with bevacizumab (SUKSES-B2) in biomarker matched relapsed or refractory small cell lung cancer.

Org: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, Department of Health Sciences and Technology, SAIHST, Sungkyungkwan University, Seoul, South Korea, Early Oncology Clinical Science, R&D Oncology, AstraZeneca, Cambridge, United Kingdom, External R&D, R&D Oncology, AstraZeneca, Seoul, South Korea, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, Samsung Genome Institute, Samsung Medical Center, Seoul, South Korea, Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea,

Abstract

Association of baseline characteristics with adverse events (AEs) in the PROpel trial of olaparib (ola) plus abiraterone (abi) as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC).

Org: Centre Hospitalier de l’Université de Montréal/CRCHUM, Centro Integrado de Oncologia de Curitiba, Radboud Universitair Medisch Centrum, Southampton General Hospital, Centre Hospitalier de Quimper,

Abstract

Efficacy and safety of PARP inhibitors (PARPi) with immune checkpoint inhibitors (ICI) in metastatic castration-resistant prostate cancer (mCRPC): A systematic review and single-arm meta-analysis.

Org: Hospital do Servidor Público do Estado de São Paulo, Faculdade de Medicina de Barbacena FAME - FUNJOB, Centro de Oncologia do Paraná,

Abstract

Synergistic effects of RPT1G, a first-in-class small molecule NAMPT inhibitor, with venetoclax and olaparib in hematological malignancies.

Org: Remedy Plan Therapeutics, UCSF Helen Diller Family Comp Cancer Ctr,

Clinical trial

Neoadjuvant Olaparib and Durvalumab for Patients With BRCA-associated Triple Negative Breast Cancer

Status: Withdrawn, Estimated PCD: 2028-09-06

Clinical trial

Immunotherapy in Combination With PARP Inhibition in Advanced Cervical Cancer Patients Functionally Competent or Deficient for the Fanconi Anemia Repair Pathway

Status: Active (not recruiting), Estimated PCD: 2030-11-01

Clinical trial

A Phase I/II Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in Patients With Relapsed/Refractory Small Cell Lung, Bladder and Prostate Cancers

Status: Recruiting, Estimated PCD: 2025-07-01

Clinical trial

A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Status: Active (not recruiting), Estimated PCD: 2020-02-23

Clinical trial

IMPACT: A Phase 0 Randomized Window-of-Opportunity Study of Novel and Repurposed Therapeutic Agents in Women Triaged to Primary Surgery for Advanced Epithelial Ovarian Cancer in Stages IIIa - IV.

Status: Completed, Estimated PCD: 2023-01-05

Clinical trial

A Phase 1/2 Study of Olaparib in Combination With Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)

Status: Active (not recruiting), Estimated PCD: 2024-06-30

Clinical trial

A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and Durvalumab (MEDI4736) in Patients With Advanced Solid Tumors

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

A Phase I Study of AZD2281 in Combination With Irinotecan in Patients With Locally Advanced or Metastatic Incurable Colorectal Cancer

Status: Completed, Estimated PCD: 2012-09-25

Clinical trial

Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors

Status: Recruiting, Estimated PCD: 2025-01-01

Clinical trial

A Phase II Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib in Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer

Status: Recruiting, Estimated PCD: 2026-04-15

Clinical trial

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Status: Recruiting, Estimated PCD: 2028-08-25

Clinical trial

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

Status: Not yet recruiting, Estimated PCD: 2026-08-01

Clinical trial

Phase IIA Trial of Short-term Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib as Firstline Therapy in Her-2 Negative Gastric/Gastroesophageal-junction (GEJ) Adenocarcinoma

Status: Active (not recruiting), Estimated PCD: 2026-09-01

Clinical trial

Pre-Surgical Window Pilot Investigation of the Effect of PARP Inhibition on the Cellular and Molecular Changes in Primary Ovarian and Breast Cancer

Status: Completed, Estimated PCD: 2021-06-15

Clinical trial

Phase II Trial of Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).

Status: Recruiting, Estimated PCD: 2024-09-01

Clinical trial

A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

Status: Active (not recruiting), Estimated PCD: 2024-06-30

Clinical trial

A Phase I/II Study of the Fluorescent PARP1 Binding Imaging Agent PARPi-FL in Patients With Oral Squamous Cell Carcinomas

Status: Recruiting, Estimated PCD: 2026-07-01

Clinical trial

An Open-label, Multicentric, Phase Ib/II Study to Assess the Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to Niraparib in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With Niraparib Since at Least 6 Months

Status: Recruiting, Estimated PCD: 2023-10-01

Clinical trial

EFFORT: Efficacy of AZD1775 in Parp Resistance; A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Women With Ovarian Cancer Who Have Progressed During PARP Inhibition

Status: Recruiting, Estimated PCD: 2024-12-30

Clinical trial

A Two-stage Simon Design Phase II Study for NOn-BRCA Metastatic BReast Cancer (MBC) Patients With Homologous Recombination Deficiency Treated With OLAparib Single Agent

Status: Terminated, Estimated PCD: 2021-07-31

Clinical trial

A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors With Expansion in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Status: Completed, Estimated PCD: 2020-07-29

Clinical trial

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women With Recurrent or Persistent Endometrial Cancer

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer With BRCA1, BRCA2, PALB2, RAD51C or RAD51D Mutations or RAD51-foci Low Test: RADIOLA TRIAL

Status: Recruiting, Estimated PCD: 2024-04-01

Clinical trial

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer - a Multicenter, Open-label, Umbrella Phase-II Study - COGNITION-GUIDE

Status: Recruiting, Estimated PCD: 2030-03-01

Clinical trial

Olaparib for Pulmonary Arterial Hypertension: a Multicenter Clinical Trial

Status: Recruiting, Estimated PCD: 2023-12-31

Clinical trial

A Phase I/II Evaluation of Olaparib in Combination With Durvalumab (Medi4736) and Tremelimumab in the Treatment of Recurrent Platinum Sensitive or Resistant or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Patients Who Carry a BRCA1 or BRCA2 Mutation

Status: Active (not recruiting), Estimated PCD: 2021-09-15

Clinical trial

A Phase I Study of DS-8201a in Combination With Olaparib in HER2-Expressing Malignancies

Status: , Estimated PCD: 2024-06-30

Clinical trial

A Phase I/Ib Study of Olaparib and ASTX727 in BRCA1/2- and HRD-mutated Tumors

Status: Recruiting, Estimated PCD: 2026-01-01

Clinical trial

A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma

Status: Recruiting, Estimated PCD: 2025-02-28

Clinical trial

A Phase Ib Study of the Oral PARP Inhibitor Olaparib With the Oral mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial, Triple Negative Breast, and Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Status: Active (not recruiting), Estimated PCD: 2025-12-30

Clinical trial

A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer

Status: Recruiting, Estimated PCD: 2026-06-30

Clinical trial

Phase II Trial of Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

Status: Recruiting, Estimated PCD: 2025-12-31

Abstract

Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial.

Org: Agomab Spain, LMU Munich, The Jikei University School of Medicine, Co-ordinating Center for Clinical Trials of the Philipps-University of Marburg, Seoul National University Hospital,

Abstract

LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).

Org: Sir Peter MacCallum Department of Oncology, St. Vincent's Hospital, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Department of Radiation Oncology, St. Vincent's Medical School,

Abstract

Phase II trial of combination pembrolizumab, olaparib, and temozolomide for patients with recurrent glioma.

Org: Memorial Sloan Kettering Cancer Center,

Abstract

Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with pembrolizumab and carboplatin as first-line treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC): A single-arm, phase 2 trial.

Org: Washington University Siteman Cancer Center, St. Louis, MO, Washington University School of Medicine in St Louis,

Abstract

Harnessing olaparib, palbociclib, and endocrine therapy: A phase I/II trial of olaparib, palbociclib and fulvestrant in patients with BRCA mutation-associated, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (HOPE).

Org: University of Pennsylvania-Abramson Cancer Center, Philadelphia, PA, University of Pennsylvania, Hospital of the University of Pennsylvania, Univ of Pa,

Abstract

Phase II study of durvalumab plus olaparib as maintenance therapy in extensive-stage small-cell lung cancer (TRIDENT): Preliminary efficacy and safety results.

Org: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, Affiliated Dongguan Hospital, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital,

Abstract

HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC).

Org: Yale School of Medicine, Foundation Medicine, Inc., Cambridge, MA, Foundation Medicine Inc, Morrisville, NC, Yale Cancer Center, Yale School of Medicine, New Haven, CT,

Abstract

A phase II study of olaparib (AZD2281) in patients (Pts) with metastatic/advanced urothelial carcinoma and other genitourinary (GU) tumors with DNA-repair defects.

Org: National Cancer Institute, Vilnius, Lithuania, NYU Langone Laura and Isaac Perlmutter Cancer Center, Dana-Farber Cancer Institute, University of California Davis, Sacramento, CA, University of Colorado Cancer Center Anschutz Medical Campus,

Abstract

Phase II clinical trial of olaparib plus pembrolizumab in the treatment of patients with advanced biliary tract cancer.

Org: MedStar Georgetown University Hospital, MedStar Harbor Hospital, Georgetown University Medical School, Georgetown Lombardi Comprehensive Cancer Center, The Ruesch Center for the Cure of Gastrointestinal Cancers,

Abstract

Dissecting small cell lung cancer subtypes with cell-free DNA fragmentomes.

Org: Delfi Diagnostics, Inc., National Cancer Center Hospital East, Kashiwa, Japan, National Cancer Institute, Vilnius, Lithuania, DELFI Diagnostics, The Johns Hopkins University School of Medicine,

Abstract

Blinded-assessment of a solution to evaluate olaparib maintenance treatment efficacy in patients with ovarian cancer from the GINECO/ENGOT PAOLA-1 trial.

Org: Centre Léon Berard, UNIV Lyon-Université Claude Bernard Lyon 1, Genotypos M.S.A., Genotypos Science Labs, AGO Study Group & Ev. Kliniken Essen-Mitte,

Abstract

Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy.

Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University, New York, NY, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering/Weill Cornell Medical College,

Abstract

A four-tier classification system for studying homologous recombination repair gene reversion mutations as a mechanism of resistance to PARP inhibitors and platinum chemotherapy.

Org: Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Sun Yat-sen Memorial Hospital of SunYat-sen University, Guangzhou, China, Sun Yat-sen University Cancer Center Gansu Hospital,

Abstract

Phase I/II study of stereotactic radiosurgery with concurrent olaparib followed by adjuvant durvalumab and physician’s choice systemic therapy in patients with breast cancer brain metastases.

Org: University of North Carolina at Chapel Hill, Memorial Sloan Kettering Cancer Center, University of North Carolina School of Medicine, Lineberger Comprehensive Cancer Center, Dana-Farber Cancer Institute,

Abstract

Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high grade glioma patients: OLA-TMZ-RTE-01.

Org: Centre François Baclesse, Centre Léon Berard, Cancer University Institute of Toulouse - Oncopole, University Hospital, CHU Bordeaux, Hospices Civils de Lyon (HCL),

Abstract

A phase II study of olaparib and durvalumab in patients with IDH-mutated cholangiocarcinoma.

Org: Princess Margaret Cancer Centre, University Health Network,

Abstract

Overall survival and subsequent therapy from a phase II study of sintilimab and anlotinib in patients with advanced or recurrent endometrial cancer.

Org: Department of Gynecologic Oncology, Gynecology and Obstetrics Center, The First Hospital of Jilin University, Changchun, China, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Sun Yat-sen University Cancer Center Gansu Hospital, Collaborative Innovation Center for Cancer Medicine,

Abstract

State-of-the-art management of HER2-negative early breast cancer: Treatment patterns among healthcare professionals and concordance with expert recommendations.

Org: Clinical Care Options, LLC, Reston, VA, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute,

Abstract

Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001.

Org: City of Hope National Medical Center, Fred Hutchiinson Cancer Research Center, SWOG Statistics and Data Management Center, Seattle, WA, Johns Hopkins University School of Medicine, University of Pennsylvania,

Abstract

Exactis-03: A phase I trial of the combination of olaparib and navitoclax in women with high grade serous ovarian cancer and triple negative breast cancer.

Org: Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Montreal, Centre De Recherche Du Centre Hospitalier De L'université De Montréal (CRCHUM), Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,

Abstract

A single-arm phase 2 study of peri-operative immune checkpoint inhibition and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer.

Org: University of Texas Southwestern Medical Center, Memorial Sloan Kettering Cancer Center, CLION-CAM Group, Cedars-Sinai Medical Center, Cedars-Sinai Cancer,

Abstract

Randomized phase 2 study of maintenance olaparib vs olaparib plus durvalumab for DNA damage repair (DDR) gene mutated unresectable or metastatic biliary tract cancer (BTC) with durable response to first-line platinum-based chemotherapy: OPTIMUM trial.

Org: Clinical Trial Center and Department of Epidemiology - IRCCS Ospedale Policlinico San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,

Abstract

Neoplastic and blood-based biomarkers of response in patients with advanced endometrial cancer: Results from NRG GY012.

Org: Odette Cancer Centre, Sunnybrook Health Sciences Centre, Duke University Medical Center, NRG Oncology, University of Iowa Hospitals and Clinics,

Abstract

Ex vivo tumor testing platform for predicting clinical response to platinum-based therapy in patients with high grade serous ovarian cancer.

Org: Radboud University Medical Center and Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands Cancer Institute, Leiden University Medical Center, Leiden University,

Abstract

Alliance A021804: A prospective, multi-institutional phase II trial evaluating temozolomide versus temozolomide and olaparib for advanced pheochromocytoma and paraganglioma.

Org: National Cancer Institute/National Institutes of Health, Dana-Farber Cancer Institute, Alliance Statistics and Data Management Center, Mayo Clinic, Lehigh Valley Health Network,

Abstract

Response to subsequent platinum-based chemotherapy post PARP inhibitor in recurrent epithelial ovarian cancer.

Org: University of Ottawa, Ottawa, ON, Canada, OHRI, The Ottawa Hospital Research Institute,

Abstract

Circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with olaparib plus 177lutetium-prostate specific membrane antigen-617 (177Lu-PSMA-617) in the LuPARP trial.

Org: Epic Sciences, Inc., Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Molecular Imaging and Therapeutic Nuclear Medicine,

Abstract

Systematic high-throughput combination drug screen to enhance poly (ADP-ribose) polymerase (PARP) inhibitor efficacy in ovarian cancer.

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, National Institute of Animal Biotechnology, Center for Translational Cancer Research, Institute of Biosciences and Technology, Texas A&M University,

Abstract

Apollo: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2, or PALB2 mutation—ECOG-ACRIN EA2192.

Org: University of Pennsylvania, Dana-Farber Cancer Institute, University of Kansas Cancer Center, Kansas City, KS, Memorial Sloan Kettering Cancer Center, Winship Cancer Center of Emory University,

Abstract

Phase 2 study of olaparib (without ADT) in men with biochemically recurrent prostate cancer (BCR) after prostatectomy.

Org: Johns Hopkins University Bloomberg School of Public Health, University of Nebraska Medical Center, Allegheny Health Network Cancer Institute - AGH, Thomas Jefferson University Hospital, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine,

Abstract

Triplet maintenance (olaparib, pembrolizumab, and bevacizumab) in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer: A multi-center, single-arm phase II study (OPEB-01).

Org: Biomedical Statistics Center, Samsung Medical Center, Seoul, South Korea, Department of Biomedical Science, CHA university, Seongnam, South Korea, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, Center for Gynecologic Cancer, National Cancer Center, Ilsandong-Gu, Goyang-Si, South Korea, Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore,

Abstract

A randomized phase II study comparing single-agent olaparib, single-agent cediranib, and the combinations of cediranib/olaparib, olaparib/durvalumab (MEDI4736), cediranib/durvalumab (MEDI4736), and olaparib/AZD5363 (capivasertib) in women with recurrent, persistent, or metastatic endometrial cancer.

Org: Cedars-Sinai Medical Center, University of Iowa Hospitals and Clinics, NRG Oncology, University of Texas MD Anderson Cancer Center, Stephenson Cancer Center/University of Oklahoma Health Sciences Center and Sarah Cannon Research Institute,

Abstract

A phase 1/2 study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress.

Org: Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, Department of Data Sciences, Dana-Farber Cancer Institute,

Abstract

Efficacy of subsequent therapies in patients (pts) with advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial according to whether disease progression occurred during or after the end of olaparib (ola) maintenance.

Org: Kliniken Essen-Mitte, Agomab Spain, Centre Jean Perrin, GINECO-Centre Jean Perrin, Clermont-Ferrand, France, Istituto Tumori Milano + Fondazione Policlinico Universitario A. Gemelli IRCCS,

Abstract

Immune correlates of outcome in patients with leiomyosarcoma (LMS) treated with durvalumab plus olaparib or cediranib: Transcriptome analysis from the DAPPER study.

Org: Princess Margaret Cancer Centre, University Health Network, Ontario Institute for Cancer Research, Toronto, ON, Canada, University of Toronto,

Abstract

Neoadjuvant PARP inhibitors in patients with early HER2-negative breast cancer harboring BRCA 1/2 germline mutations: A systematic review and meta-analysis.

Org: Universidade Estadual do Centro Oeste - UNICENTRO, Guarapuava, Brazil, Princess Margaret Hospital, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Catholic University of Pelotas, Universidade de Brasília,

Abstract

AXL pathway as a target to overcome resistance to PARP inhibitors in high-grade serous ovarian (HGSOC) and triple-negative breast cancer (TNBC) cell lines.

Org: Hospital Clinico Universitario de Valencia; INCLIVA; GEICAM Spanish Breast Cancer Group, INCLIVA-Biomedical Research Institute, CIBERONC - ISCIII, Instituto de Investigación Sanitaria (INCLIVA), Translational Oncology and Pathology Group,

Abstract

Association of KMT2C loss-of-function mutations in circulating tumor DNA and prolonged response to the combination of PARPi and PI3Ki.

Org: Mayo Clinic, Beth Israel Deaconess Medical Center, Harvard Medical School, Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute,

Abstract

Trends in the use of maintenance therapy in ovarian cancer.

Org: University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center, Health Services Research Department, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,

Abstract

The clinical value of homologous recombination deficiency score in prostate cancer.

Org: Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China, Shanghai OrigiMed Co., Ltd, Shanghai, China, Shanghai OrigiMed Co., Ltd., Shanghai, China,

Abstract

PARPi monotherapy as first-line maintenance following chemotherapy + bevacizumab in advanced ovarian cancer.

Org: South Carolina Oncology Associates, Precision Q, Integra Connect, GSK Research and Development Upper Providence, Collegeville, PA,

Abstract

Real world treatment patterns and survival by germline BRCA (gBRCA) mutation status in patients with HER2-negative early breast cancer (eBC) in the US community oncology setting: A retrospective observational study.

Org: Compass Oncology, Merck & Co., Inc., Ontada, Memorial Sloan Kettering Cancer Center, AstraZeneca,

Abstract

Safety and survival in adult women with platinum sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study.

Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Bayindir Sogutozu Hospital, Istanbul University Dep of Oncology, Hacettepe University Faculty of Medicine Department of Medical Oncology, Istanbul University Cerrahpasa Faculty of Medicine,

Abstract

Evolution of breast cancer management in the Dominican Republic in the 21st century.

Org: FUNDEONCAP, IOHP, Dominican Society of Oncology,

Abstract

Use of PARPi among patients with HER2+ve MBC: Results from a real world dataset.

Org: Mediclinic City Hospital, TriNetX Europe,

Abstract

Outcomes of myeloid malignancies in patients previously treated with PARP inhibitors for solid malignancies: A single institution experience.

Org: University of Texas MD Anderson Cancer Center, The University of Texas at MD Anderson Cancer Center, MD Anderson Cancer Center, Department of Leukemia,

Abstract

Real-world impact of olaparib use in patients (pts) with advanced pancreatic cancer (PC) harboring germline BRCA1/2 (gBRCA) mutations.

Org: University of Verona, Oncology Section, Verona University Hospital Trust (AOUI Verona), IRCCS Ospedale San Raffaele, Università Vita-Salute San Raffaele Facoltà di Medicina e Chirurgia, University of Bologna,

Abstract

Tumor sensitization to PARP inhibitors by DNA damaging synthetically lethal acylfulvenes.

Org: Lantern Pharma,

Abstract

Reliance of agency-approved and guideline-recommended therapies on surrogate endpoints in triple-negative breast cancer (TNBC).

Org: The Larvol Group, LLC, Labcorp Drug Development Inc., Princeton, NJ, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Trust,

Abstract

Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor (PARP) in patients with newly diagnosed ovarian cancer: A systematic review and meta-analysis.

Org: Centro de Oncologia do Parana, Princess Margaret Hospital, Catholic University of Pelotas, Universidade de Brasília, UNICENTRO,

Abstract

Real world utilization and outcomes of immunotherapy regimens in metastatic castration resistant prostate cancer (mCRPC).

Org: Tisch Cancer Institute, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY,

Abstract

The combination of APR-246 and carboplatin in olaparib-resistant high grade serous ovarian cancer (HGSOC) and triple negative breast cancer (TNBC) cell lines.

Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria (INCLIVA), Translational Oncology and Pathology Group, La Paz University Hospital-IdiPAZ,

Abstract

Olaparib in HR-deficient (HRD), metastatic triple-negative breast cancer (TNBC) and relapsed ovarian cancer (ROC) without germline mutations in BRCA1 or BRCA2: Phase 2 EMBRACE trial.

Org: NHMRC Clinical Trials Centre, The University of Sydney, St George Hospital, The University of Melbourne, Royal North Shore Hospital, Sydney, Australia,

Abstract

Org: CHRU Besançon Hôpital J.Minjoz, Besançon, France, Centre Hospitalier de l’Université de Montréal/CRCHUM, Université de Montreal, Montreal, QC, Canada, Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Durham, NC, Department of Urology, Keio University School of Medicine, Tokyo, Japan, Centro Integrado de Oncologia de Curitiba, Curitiba, Brazil,

Abstract

Effect of testing for BRCA1/2 on outcomes in patients with ovarian cancer treated with PARPi in 1st line maintenance (1LM).

Org: Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, Integra Connect PrecisionQ, Illumina, Inc., Integra Connect,

Abstract

Efficacy of PARP inhibitors in patients with metastatic castration resistant prostate carcinoma: A meta-analysis of phase III randomized controlled trials.

Org: Community Hospital of San Bernardino, Abbott Northwestern Hospital, SSM St Mary's hospital, University of California Riverside, SSM St Louis University hospital,

Product

Olaparib plus Bevacizumab

Abstract

Measuring real-world concordance with evidence-based guidelines for genetic testing in patients with breast cancer: A retrospective quality review.

Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute,

Abstract

Clinical benefit of personalized treatment following high throughput sequencing in metastatic melanoma: A national retrospective study.

Org: Dermatology and Skin Cancer Department, AP-HM Marseille, Dermatology Departement, Cochin Hospital, APHP,Université Paris Cité, Paris, France, CHU de Bordeaux, Cochin Hospital,

Abstract

BRCA1 and RAD51 methylation impact on outcome in patients with advanced ovarian cancer: A PAOLA-1 ancillary study.

Org: APHP-INSERM U1149 Universite Paris Diderot, European Georges Pompidou Hospital, Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Université,

Clinical trial

Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness

Status: Recruiting, Estimated PCD: 2025-12-31

Abstract

https://www.abstractsonline.com/pp8/#!/10828/presentation/10431

Abstract

https://www.abstractsonline.com/pp8/#!/10517/presentation/20266

Abstract

https://www.abstractsonline.com/pp8/#!/10517/presentation/20248

Clinical trial

Multicenter, Randomized, Phase Ib/IIb Study to Evaluate the Efficacy and Tolerability of Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone, in Patients With EGFR Mutation Positive Advanced Non-small-cell Lung Cancer

Status: Completed, Estimated PCD: 2016-07-01

Clinical trial

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

Status: Not yet recruiting, Estimated PCD: 2026-09-01